

#UC2019

MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?

MONDAY, OCTOBER 28, 2019

6:00 AM to 7:30 AM

Hot breakfast served at 5:30 AM

**MIPS Improvement Activity +
Earn ABIM MOC Credit**

This event is neither sponsored by nor endorsed by ACG

Co-provided by:



MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?




Improved long-term clinical outcomes in patients with ulcerative colitis (UC) include sustained clinical remission, decreased need for surgery, decreased hospitalization rates, and reduced risk of colon cancer. Mucosal healing is reported to be associated with these improved outcomes, with some experts suggesting that histologic inflammation is a better predictor of future clinical relapse than endoscopic appearance alone, as endoscopic findings are not always consistent with histologic activity and tend to underestimate the depth of mucosal damage relative to the histologic findings.

Clinical studies have demonstrated that histologic improvements may be associated with better clinical outcomes, including reduced colorectal cancer and relapse rates.

This CME Outfitters symposium features expert faculty in an interactive discussion utilizing real-life case scenarios to highlight optimal approaches to treat and monitor patients with UC.

FACULTY



David T. Rubin, MD, FACG, AGAF, FACP, FASGE (Chairman)

Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL



Miguel Regueiro, MD, AGAF, FACG, FACP

Professor and Chair
Department of Gastroenterology, Hepatology and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic
Cleveland, OH

TARGET AUDIENCE

Gastroenterologists, gastroenterology fellows, physician assistants, nurse practitioners, and nurses

SYMPOSIUM INFORMATION

For more information on this symposium visit

www.CMEOutfitters.com/UC2019

or scan the QR code on the right.



MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?



LEARNING OBJECTIVES

- Evaluate the efficacy of current and emerging UC treatments in achieving mucosal healing and steroid-free remission.
- Apply approaches to achieve mucosal healing in patients with UC.
- Implement strategies to monitor patients with UC for endoscopic and histologic disease activity in order to guide therapy.

COMMERCIAL SUPPORT

Supported by educational grants from Genentech and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

ACCREDITATION STATEMENTS

CME Credit (Physicians): USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by the Accreditation Council for Continuing Medical Education.

CNE Credit (Nurses): Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for *AMA PRA Category 1 Credit*[™] through the American Academy of Nurse Practitioners (AANP). AANP will accept *AMA PRA Category 1 Credit*[™] from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

ABIM MOC: MOC Points available for Internal Medicine and General Medicine Board Certified Physicians. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Within 60 days of the end of the activity, ABIM MOC points will be reported on your behalf.

For more information about ACCME accreditation and ABIM MOC for this activity, please email cpdsupport@health.usf.edu.

Learning Format: Live activity

By providing your ABIM number, you consent to have CME Outfitters and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.



MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?



David T. Rubin, MD, FACP, AGAF, FACP, FASGE (Chairman)

Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

BIOGRAPHY

Dr. Rubin is Chief of the Section of Gastroenterology, Hepatology and Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), and the American College of Physicians (ACP) as well as an active national member of the Crohn's & Colitis Foundation (CCF) and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator's Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCF Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair-Elect of the National Scientific Advisory Committee of the CCF. He is an Associate Editor of the journal *Gastroenterology* and Co-Editor of the ACG On-Line Educational Universe.

Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its 3rd edition, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD as well as cancer in IBD and novel paradigms. He is also first author of the ACG Guidelines for ulcerative colitis. His current research is in the area of progressive complications from uncontrolled inflammation, the doctor-patient relationship in IBD, and a variety of collaborative studies related to the microbiome and intestinal disease. He is also a featured media contact for issues related to IBD (satellite radio, television, and print media) and maintains a popular twitter feed @IBDMD (> 6,000 followers). His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.

MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?



Miguel Regueiro, MD, AGAF, FACP, FACP

Professor and Chair
Department of Gastroenterology, Hepatology and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in
Gastroenterology and Hepatology
Cleveland Clinic
Cleveland, OH

BIOGRAPHY

Dr. Regueiro earned his bachelor's degree at the University of Pennsylvania and his medical degree at Drexel (Hahnemann) University. He completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School's Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure and was honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

He is currently the Chair of the Department of Gastroenterology, Hepatology and Nutrition and is the Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology at the Cleveland Clinic in Ohio.

Dr. Regueiro's main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn's disease. Recently, he has been involved in transformative medicine initiatives and developing new models of health care, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of health care delivery around these novel programs.

MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?



DISCLOSURE DECLARATION

It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dical Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology; as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and as Co-Founder of GoDuRn, LLC.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board and is a consultant for AbbVie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Disclosures were obtained from the USF Health staff: No disclosures to report.

CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

OBTAINING CREDIT

Learners must complete the posttest and evaluation on the iPads. CME Outfitters will email their certificates within 30 days to the email provided upon login to the iPad audience response system.

DOWNLOADABLE RESOURCES

Downloadable resources are available at

www.cmeoutfitters.com/UC2019Resources



MUCOSAL HEALING AND STEROID-FREE REMISSION IN ULCERATIVE COLITIS:

What Is the Role of Current and Emerging Treatments?



INSTRUCTIONS FOR INTERACTIVE TECHNOLOGY

If you would like to use your tablet or mobile device to answer polling questions, view the onsite presentations, and submit questions to the faculty, please follow the instructions below:

1. Get Connected

- Please connect to the CME Outfitters network with your mobile device or laptop. This network does not have a password.
*** Please note that this network is a local network and does NOT mean you're connected to the internet.**
- Once you have joined the network, go to arraylearn.com.
- You are now connected to the symposium. All content and polling questions can be viewed on your device as long as you are connected to the network listed above.

2. Ask a Question to the Faculty

- Please click on "Ask a Question" and type your question. Please include the faculty member's name if the question is specifically for him or her. Your question will be sent to the faculty for the question and answer portion of the session.

3. View and Take Notes on Presentation Slides

- Please click on the "Take a Slide Note" button. If you did not enter your email address when you joined the meeting, you will be required to do so for note-taking. When the meeting is complete, all your notes will be emailed to you within five business days.

ENGAGE WITH US ON TWITTER

Follow us on [@cmeoutfitters](https://twitter.com/cmeoutfitters) for announcements about upcoming CME opportunities, health care news, and more!

We will be live-tweeting from today's symposium — tweet us your questions using [#UC2019](https://twitter.com/hashtag/UC2019)

THANK YOU FOR JOINING US TODAY!

